A new trading day began on Friday, with Cardiff Oncology Inc (NASDAQ: CRDF) stock price up 7.18% from the previous day of trading, before settling in for the closing price of $3.62. CRDF’s price has ranged from $2.01 to $5.64 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 22.80% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 13.83%. With a float of $60.75 million, this company’s outstanding shares have now reached $66.53 million.
In an organization with 33 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 58.04%, operating margin of -10876.83%, and the pretax margin is -10201.67%.
Cardiff Oncology Inc (CRDF) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cardiff Oncology Inc is 8.68%, while institutional ownership is 42.24%. The most recent insider transaction that took place on Dec 17 ’24, was worth 14,905. In this transaction Chief Financial Officer of this company bought 2,752 shares at a rate of $5.42, taking the stock ownership to the 65,316 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Chief Financial Officer bought 2,400 for $5.00, making the entire transaction worth $12,000. This insider now owns 67,716 shares in total.
Cardiff Oncology Inc (CRDF) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.81% during the next five years compared to 19.36% growth over the previous five years of trading.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Here are Cardiff Oncology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 437.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.93, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.97 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Let’s dig in a bit further. During the last 5-days, its volume was 1.16 million. That was better than the volume of 1.12 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 83.87%. Additionally, its Average True Range was 0.23.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 57.79%, which indicates a significant decrease from 95.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.24% in the past 14 days, which was lower than the 80.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.94, while its 200-day Moving Average is $3.22. However, in the short run, Cardiff Oncology Inc’s stock first resistance to watch stands at $4.00. Second resistance stands at $4.13. The third major resistance level sits at $4.33. If the price goes on to break the first support level at $3.68, it is likely to go to the next support level at $3.48. Assuming the price breaks the second support level, the third support level stands at $3.36.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
With a market capitalization of 258.12 million, the company has a total of 66,526K Shares Outstanding. Currently, annual sales are 680 K while annual income is -45,430 K. The company’s previous quarter sales were 110 K while its latest quarter income was -13,430 K.
